-The Hindu Health sector outlay tripled to Rs.3-lakh crore Prime Minister Manmohan Singh said on Saturday that the allocation for the health sector during the 12th Plan had been increased three times over the previous Plan allotment to address complex challenges. The outlay in the 12th Plan had been fixed at Rs. 3-lakh crore, which was 1.95 per cent of the Gross Domestic Product. During the last Plan period, the sector had got...

-The Times of India A day after India Against Corruption (IAC) charged the government with selling out to Reliance Industries Ltd (RIL) on the company's KG-D6 gas field off the Andhra coast, the oil ministry on Thursday hit back by describing the allegations as "baseless and frivolous".  In a point-wise rebuttal to IAC charges, a ministry statement — issued after former oil minister Mani Shankar Aiyar met incumbent Veerappa Moily for over...

-The Indian Express Petroleum Minister Veerappa Moily on Thursday refuted Arvind Kejriwal’s accusations of the UPA government favouring Reliance Industries Ltd saying that the decisions were taken objectively “without fear or favour” and assured that his ministry would continue to uphold transparency. “The ministry is committed to upholding the rule of law and decisions are taken objectively without any fear or favour. The system is not influenced or guided by whims and...

-Live Mint There are also ways in which we can help Indian institutions that have come to us seeking access to our technologies Bangalore: A key perception change is emerging in the global pharmaceutical industry on the long-established divide between the so-called generics and innovative business. While the two are still at loggerheads in several developed as well as developing markets, the world’s top drugmakers are reinventing the wheel. Paris-based Sanofi SA,...

-The Times of India Medicines in India may not be sold under brand names in the near future. In its biggest move to push generic drugs and do away with brand names, the Union health ministry has ordered states to stop issuing licence for the manufacture or sale of drugs on the basis of their brand name. All pharmaceutical firms applying for licence to market or manufacture fixed dose combination (FDC) drugs will...